BLIS K12 Gains Australian Regulatory Approval
10 Birch Street
PO Box 5804
Dunedin 9058
New Zealand
Telephone: 03 474 1338
Fax: 03 474 9050
Email: info@blis.co.nz
Website: www.blis.co.nz
21 November 2017
BLIS K12
TM
Gains Australian Regulatory Approval
Blis Technologies has received notification from the Australian Therapeutic
Goods Administration, that its probiotic strain Streptococcus salivarius BLIS
K12
TM
has been approved as an active ingredient for Listed Complementary
Medicines.
CEO Brian Watson said, “This approval will allow us to enter the Australian
market with our finished product portfolio based on BLIS K12
TM
. The
Australian probiotic supplement market is the 6
th
largest globally and it is
growing at 46% annually so represents a priority growth market for
Blis. Within the NZ market, Blis branded BLIS K12
TM
Throat Lozenges are
now ranked as the 2nd largest brand in ‘NZ Pharmacy Throat Lozenge’
category and the fastest growing of the top 5 brands. This gives us a lot of
confidence in the market potential of the larger Australian market and we are
accelerating our plans to launch in 2018 based on this important milestone.”
Brian Watson
Chief Executive
Data sourced from publicly available filings. Our datasets may not be complete. Automated analysis can produce errors. If you believe any data on this page is incorrect, please contact us at hello@nzxplorer.co.nz. For informational purposes only. Not investment advice.
Other issuers discussed similar conditions around this time
Matched by meaning across NZX announcement text, not keywords — based on our semantic index of announcement bodies.
- PHL — Promisia Healthcare Limited: Promisia Integrative Limited – Third Quarter Sales Update2017-10-18
“Promisia Integrative Limited (NZX:PIL) is a company focused on developing and marketing unique therapeutic natural products with proven safety and efficacy from robust data. Our goal is to add scientific methodology and validity to an industry that is often perceived as unscie…”
- AFT — AFT Pharmaceuticals Limited: Interim Report FY20182017-11-22
“Liquid study in Australia, Mexico and New Zealand. Preliminary analysis of the Maxigesic IV study has confirmed that the study met the primary endpoints with a high degree of clinical and statistical significance. This is a significant achievement and has reduced the clini…”
- MOV — MOVE Logistics Group Limited: Acquisition of Transport Investments Limited business2017-11-17
“3 8246810_1 Following the New BIL In-Specie Distribution, New BIL intends to apply to compliance list on the NZX Main Board to support an anticipated future capital raising initiative and provide liquidity to shareholders. Benefits of the New BIL In-Specie Distributio…”